Ratings Sonova Holding AG

Equities

SOON

CH0012549785

Real-time Estimate Cboe Europe Other stock markets 08:06:24 29/04/2024 BST			5-day change	1st Jan Change
257 ^CHF	-0.02%		+3.63%	-6.34%

02-28	Equita SIM Initiates Coverage on Sonova with Hold Recommendation	MT
01-08	Indices: Wishing you a Happy New Year and, above all, good health!

Summary

The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
With a 2024 P/E ratio at 26.91 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
With an enterprise value anticipated at 4.51 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SONOVA HOLDING AG	-6.34%	16.75B		A
STRAUMANN HOLDING AG	+1.84%	24.07B		B
COCHLEAR LIMITED	+8.42%	13.7B		B
DEMANT A/S	+10.34%	10.18B		B-
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-17.75%	2.06B		-
EMBLA MEDICAL HF.	+6.38%	1.79B		B+
MODERN DENTAL GROUP LIMITED	+12.56%	589M		-
ANGEL ROBOTICS CO., LTD.	0.00%	400M	-	-
DELCATH SYSTEMS, INC.	+27.40%	135M		-
INTEGRUM AB	+21.80%	93.49M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes